Uproleselan
- Generic Name
- Uproleselan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C60H109N3O27
- CAS Number
- 1983970-12-2
- Unique Ingredient Identifier
- PE952ANF83
- Background
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
- Associated Conditions
- -
- Associated Therapies
- -
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Malika Kapadia
- Target Recruit Count
- 1
- Registration Number
- NCT05569512
- Locations
- πΊπΈ
Helen DeVos Children's Hospital/Spectrum Health, Grand Rapids, Michigan, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Mixed Phenotype Acute LeukemiaDown SyndromeMyelodysplastic Syndrome Post Cytotoxic TherapyRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT05146739
- Locations
- πΊπΈ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Lena Napolitano, MD
- Target Recruit Count
- 6
- Registration Number
- NCT05057221
- Locations
- πΊπΈ
The University of Michigan, Ann Arbor, Michigan, United States
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05054543
- Locations
- π¨π³
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
π¨π³The First Affiliated Hospital of Zhejiang University, Hangzhou, China
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 16
- Registration Number
- NCT04964505
- Locations
- πΊπΈ
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT04848974
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04839341
- Locations
- π¨π³
The First Affiliated Hospital of Zhejiang University, Hangzhou, China
π¨π³Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT04682405
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 670
- Registration Number
- NCT03701308
- Locations
- πΊπΈ
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈCommunity Cancer Institute, Clovis, California, United States
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 388
- Registration Number
- NCT03616470
- Locations
- πΊπΈ
Rush University Medical Center, Chicago, Illinois, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
πΊπΈSeattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.